Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2013

01-07-2013 | Laboratory Investigation

High plasma-GFAP levels in metastatic myxopapillary ependymoma

Authors: Ayseguel Ilhan-Mutlu, Anna S. Berghoff, Julia Furtner, Karin Dieckmann, Irene Slavc, Thomas Czech, Christine Marosi, Ludwig Wagner, Matthias Preusser

Published in: Journal of Neuro-Oncology | Issue 3/2013

Login to get access

Abstract

Myxopapillary ependymoma (MPE) is a rare tumor of the distal spinal cord. Despite benign histopathology, local recurrences occur in ~30 % of patients and distant metastases have been described in few cases. MPE tumor cells typically express glial fibrillary acidic protein (GFAP), which could be released to the circulation. In this current report, we investigated circulating plasma-GFAP in a series of MPE patients. We analyzed circulating plasma-GFAP using a commercially available ELISA kit in 3 patients with completely resected MPE, 1 patient with locally advanced MPE and 2 patients with pleuropulmonary metastases of MPE. As controls we used blood samples of age and gender-matched healthy volunteers (n = 3), 6 glioblastoma patients with known plasma-GFAP status (positive for 3 and negative for 3 patients) and 3 brain metastases patients with known plasma-GFAP negativity. We found very high concentrations of plasma-GFAP in two MPE patients with pleuropulmonary metastases, while in none of the other MPE patients circulating plasma-GFAP was detectable. Circulating GFAP could be useful as marker for early detection or follow-up of distant metastases in MPE patients.
Literature
1.
go back to reference Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG (1991) Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 22:1254–1258CrossRef Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG (1991) Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 22:1254–1258CrossRef
2.
go back to reference Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380–384PubMedCrossRef Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380–384PubMedCrossRef
3.
go back to reference Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25:1439–1451CrossRef Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25:1439–1451CrossRef
4.
go back to reference Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, Raabe A, Neumann-Haefelin T, Steinmetz H, Sitzer M (2006) Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 77:181–184PubMedCrossRef Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, Raabe A, Neumann-Haefelin T, Steinmetz H, Sitzer M (2006) Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 77:181–184PubMedCrossRef
5.
go back to reference Ilhan-Mutlu A, Wagner L, Widhalm G, Wohrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M (2013) Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev. doi:10.1007/s10143-012-0401-6 PubMed Ilhan-Mutlu A, Wagner L, Widhalm G, Wohrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M (2013) Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev. doi:10.​1007/​s10143-012-0401-6 PubMed
6.
go back to reference Ilhan A, Furtner J, Birner P, Rossler K, Marosi C, Preusser M (2011) Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels. J Clin Oncol. 29:e756–e757PubMedCrossRef Ilhan A, Furtner J, Birner P, Rossler K, Marosi C, Preusser M (2011) Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels. J Clin Oncol. 29:e756–e757PubMedCrossRef
7.
go back to reference Ilhan I, Berberoglu S, Kutluay L, Maden HA (1998) Subcutaneous sacrococcygeal myxopapillary ependymoma. Med Pediatr Oncol 30:81–84PubMedCrossRef Ilhan I, Berberoglu S, Kutluay L, Maden HA (1998) Subcutaneous sacrococcygeal myxopapillary ependymoma. Med Pediatr Oncol 30:81–84PubMedCrossRef
8.
go back to reference Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336–3341PubMedCrossRef Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336–3341PubMedCrossRef
9.
go back to reference Louis DN, Ohgaki H, Wiestler O, Cavenee W (2007) WHO classification of tumours of the central nervous system, 4th edn. Blackwell, Oxford Louis DN, Ohgaki H, Wiestler O, Cavenee W (2007) WHO classification of tumours of the central nervous system, 4th edn. Blackwell, Oxford
10.
go back to reference Notturno F, Caporale CM, De Lauretis A, Uncini A (2008) Glial fibrillary acidic protein: a marker of axonal Guillain–Barre syndrome and outcome. Muscle Nerve 38:899–903PubMedCrossRef Notturno F, Caporale CM, De Lauretis A, Uncini A (2008) Glial fibrillary acidic protein: a marker of axonal Guillain–Barre syndrome and outcome. Muscle Nerve 38:899–903PubMedCrossRef
11.
go back to reference Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA Jr, Blair C, Romans KE, Holdhoff M (2012) Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol 109:123–127PubMedCrossRef Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA Jr, Blair C, Romans KE, Holdhoff M (2012) Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol 109:123–127PubMedCrossRef
12.
go back to reference Pica A, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC (2009) The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 74:1114–1120PubMedCrossRef Pica A, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC (2009) The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 74:1114–1120PubMedCrossRef
13.
go back to reference Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Ozyigit G, Preusser M (2012) Outcome of patients with primary spinal myxopapillary ependyomama: a retrospective study from the MD Anderson Cancer Center and Rare Cancer Network. EANO 10th meeting, Marseille/France, September 2012 Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Ozyigit G, Preusser M (2012) Outcome of patients with primary spinal myxopapillary ependyomama: a retrospective study from the MD Anderson Cancer Center and Rare Cancer Network. EANO 10th meeting, Marseille/France, September 2012
Metadata
Title
High plasma-GFAP levels in metastatic myxopapillary ependymoma
Authors
Ayseguel Ilhan-Mutlu
Anna S. Berghoff
Julia Furtner
Karin Dieckmann
Irene Slavc
Thomas Czech
Christine Marosi
Ludwig Wagner
Matthias Preusser
Publication date
01-07-2013
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1134-2

Other articles of this Issue 3/2013

Journal of Neuro-Oncology 3/2013 Go to the issue